Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2023.216509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Jirapat Namkaew und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Biology, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan; ER Stress Research Institute…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Lung cancer, primarily non-small-cell lung cancer (NSCLC), is a significant cause of cancer-related mortality worldwide. Cisplatin-based chemotherapy is a standard treatment for NSCLC; however, its effectiveness is often limited due to the development of resistance, leading to NSCLC recurrence. Thus, the identification of effective chemosensitizers for cisplatin is of paramount importance. The integrated stress response (ISR), activated by various cellular stresses and mediated by eIF2α kinases, has been implicated in drug sensitivity. ISR activation globally suppresses protein synthesis while selectively promoting the translation of ATF4 mRNA, which can induce pro-apoptotic proteins such as CHOP, ATF3, and TRIB3. To expedite and economize the development of chemosensitizers for cisplatin treatment in NSCLC, we employed a strategy to screen an FDA-approved drug library for ISR activators. In this study, we identified mifepristone as a potent ISR activator. Mifepristone activated the HRI/eIF2α/ATF4 axis, leading to the induction of pro-apoptotic factors, independent of its known role as a synthetic steroid. Our in vitro and in vivo models demonstrated mifepristone's potential to inhibit NSCLC re-proliferation following cisplatin treatment and tumor growth, respectively, via the ISR-mediated cell death pathway. These findings suggest that mifepristone, as an ISR activator, could enhance the efficacy of cisplatin-based therapy for NSCLC, highlighting the potential of drug repositioning in the search for effective chemosensitizers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Biology, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan; ER Stress Research Institute Inc., Tokushima, 770-8503, Japan.
- Division of Molecular Biology, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan; Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima Un…
- Division of Molecular Biology, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan.
- Division of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, 770-8503, Japan; Laboratory of Biofunctional Molecular Medicine, Center for Drug Design Research, National Institute…
Zitieren
APA
Namkaew, J., Zhang, J., Yamakawa, N., Hamada, Y., Tsugawa, K., Oyadomari, M., Miyake, M., Katagiri, T., & Oyadomari, S. (2024). Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216509
Vancouver
Namkaew J, Zhang J, Yamakawa N, Hamada Y, Tsugawa K, Oyadomari M, et al. Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Letters. 2024. doi:10.1016/j.canlet.2023.216509
BibTeX
@article{Namkaew2024,
author = {Namkaew, Jirapat and Zhang, Jun and Yamakawa, Norio and Hamada, Yoshimasa and Tsugawa, Kazue and Oyadomari, Miho and Miyake, Masato and Katagiri, Toyomasa and Oyadomari, Seiichi},
title = {Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2023.216509}
}
EUVIMED